New hope for elderly lymphoma patients: targeted combo shows promise
NCT ID NCT07493148
First seen Apr 08, 2026 · Last updated May 21, 2026 · Updated 5 times
Summary
This study tests a new drug combination for people aged 70 and older who have a specific type of aggressive lymphoma (DLBCL) that has not been treated before. Participants receive a targeted drug (chidamide) plus a reduced-dose chemotherapy, followed by maintenance therapy with chidamide and an antibody. The goal is to see if this approach helps control the disease longer without severe side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Bethune Hospital of Jilin University
RECRUITINGChangchun, Jilin, 130021, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.